Navigation Links
Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Date:3/13/2008

- Dendreon to Hold Conference Call Today, March 13, 2008 at 11:00 AM ET -

SEATTLE, March 13 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2007. Revenues for the year ended December 31, 2007 were $743,000 compared to $273,000 for the year ended December 31, 2006. Revenues for the fourth quarter of 2007 were $28,000, compared to $86,000 for the same period in 2006.

The net loss for the year ended December 31, 2007 was $99.3 million, or $1.20 per share, compared to $91.6 million, or $1.27 per share for the year ended December 31, 2006. Net loss in the fourth quarter of 2007 was $27.0 million or $0.32 per share, compared to a net loss of $21.5 million, or $0.28 per share, for the same period in 2006. Dendreon's total operating expenses for the year ended December 31, 2007 were $102.4 million compared to $97.6 million in 2006. Net cash used in operating activities in 2007 was $82.6 million compared to $80.8 million in 2006.

As of December 31, 2007, Dendreon had approximately $120.6 million in cash, cash equivalents, and short-term and long-term investments compared to $121.3 million as of December 31, 2006.

Recent Highlights:

-- The FDA agreed to amend the IMPACT (IMmunotherapy for Prostate

AdenoCarcinoma Treatment) Special Protocol Assessment (SPA),

accelerating the expected timeline for final results from the study by

approximately one year while maintaining comparable power to the

previous SPA. In addition, the FDA reconfirmed that either a positive

interim or final analysis of survival would support licensure and

enable Dendreon to amend the company's biologic
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 “This kit has an improved ... from 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin ... benefit to plant owners and USDA-GIPSA inspection agencies that have ... Testing can take place in a matter of minutes with ... plant test the feed and grain before accepting it, but ...
(Date:8/28/2014)... Spin-charge converters are important devices in spintronics, an ... charge of electrons but also on their spin ... transformation of electric into magnetic signals and vice ... Sinova from the Institute of Physics at Johannes ... the UK, Prague, and Japan, has for the ...
(Date:8/28/2014)... The ability for organizations to attract top ... individuals to perform at the highest of levels, are ... to compete in this post–recession era. The pharmaceutical ... the sector increasingly focuses on the importance of employee-fit ... real results on the organization's development and the innovation ...
(Date:8/28/2014)...   SunTrust Robinson Humphrey (STRH) today ... its equity research team in biotechnology and oilfield ... equity research demonstrates our commitment to providing our ... their investment decision making," said Biff Woodruff ... to make significant investments in differentiated content at ...
Breaking Biology Technology:A new, tunable device for spintronics 2A new, tunable device for spintronics 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... - Listed companies to present at Therapeutic ... 2 Elsevier Business Intelligence and Windhover ... list. The list delivers projects and companies with high-value assets for ... in deals. This year,s list includes a Top 10 ...
... significantly improve the efficiency at which gallium nitride ... The devices are believed to be the first ... creation of an electrical charge in a piezoelectric ... mechanical strain to the microwires, researchers at the ...
... Oct. 31, 2011 Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... 30, 2011. For the third quarter of 2011, ... fully diluted share outstanding, compared to net income of $3.3 million, ... in 2010. For the nine months ended September 30, 2011, the ...
Cached Biology Technology:Windhover Announces the "Top Biopharma Projects to Watch" 2Windhover Announces the "Top Biopharma Projects to Watch" 3Zinc oxide microwires improve the performance of light-emitting diodes 2Zinc oxide microwires improve the performance of light-emitting diodes 3Neurocrine Biosciences Reports Third Quarter 2011 Results 2Neurocrine Biosciences Reports Third Quarter 2011 Results 3Neurocrine Biosciences Reports Third Quarter 2011 Results 4Neurocrine Biosciences Reports Third Quarter 2011 Results 5Neurocrine Biosciences Reports Third Quarter 2011 Results 6Neurocrine Biosciences Reports Third Quarter 2011 Results 7Neurocrine Biosciences Reports Third Quarter 2011 Results 8
(Date:9/1/2014)... has improved steadily in recent yearsspurred in large part ... poor and disparities continue to widen among socioeconomic and ... School of Public Health (HSPH). , "The study provides ... efforts by many groups and individuals to improve U.S. ... indicates that these efforts need to be expanded," said ...
(Date:9/1/2014)... that corals whose calcium-carbonate skeletons form the ... that rely entirely on ocean currents to deliver ... now scientists at MIT and the Weizmann Institute ... they are far from passive, engineering their environment ... enhance their ability to exchange nutrients and dissolved ...
(Date:9/1/2014)... It may be possible to train the brain ... according to new research by scientists at the Jean ... HNRCA) at Tufts University and at Massachusetts General Hospital. ... Diabetes , a brain scan study in adult men ... the addictive power of unhealthy food while also increasing ...
Breaking Biology News(10 mins):Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Nature's tiny engineers 2Nature's tiny engineers 3Training your brain to prefer healthy foods 2
... forces laboratory leukemia cells to commit cell suicide, according ... that within 24 hours, 76 percent of leukemia cells ... The investigators, who report their findings in the January ... a journal of the American Association for Cancer Research, ...
... who took beta carotene or vitamin C or E or ... cancer as women who did not take the supplements, according ... 30 online issue of the Journal of the National ... whose diets are high in fruits and vegetables, and thus ...
... new clinical trial suggests that long-term use of candesartan, ... reduce the symptoms of genetic heart disease. The ... candesartan on left ventricular hypertrophy and function in non-obstructive ... January issue of The Journal of Molecular Diagnostics ...
Cached Biology News:Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds 2Vitamins C and E and beta carotene again fail to reduce cancer risk in randomized controlled trial 2
PC based system for superior chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Rabbit Polyclonal antibody to Perilipin Applications: This antibody is useful for Western blot anlaysis where a band at ~60 kDa is seen....
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
... Mch3 Lyophilized solid. Highly ... and kinetics, cleavage of target substrates, and inhibitor screening. ... One unit is defined as the amount of ... No. 235400 per hour at 37 C at saturated ...
Biology Products: